{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-010864","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2022-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.003054+00:00","generated_at":"2026-06-26T21:59:40.763383+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Trevi: Phase 2 CANAL interim p<0.0001 (52% cough reduction); PRISM enrollment done","bullets":["Phase 2 CANAL interim analysis: 52% placebo-adjusted reduction in daytime cough events (p<0.0001); enrollment ended early; full data Q3 2022.","Phase 2b/3 PRISM trial (pruritus in prurigo nodularis) completed enrollment Jan 31, 2022; top-line data expected Q2 2022.","Q4 2021 net loss $8.5M vs $9.5M in Q4 2020; full-year net loss $33.9M vs $32.8M in 2020.","Cash and equivalents of $36.8M as of Dec 31, 2021.","KOL webinar on IPF chronic cough set for March 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-010864","json":"https://secwatch.observer/filing/0001564590-22-010864.json","markdown":"https://secwatch.observer/filing/0001564590-22-010864.md","text":"https://secwatch.observer/filing/0001564590-22-010864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022010864/0001564590-22-010864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022010864/trvi-8k_20220317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:59:40.763383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}